Andrew D. Steele
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Andrew D. Steele has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Ben Shen
The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology
10 shared publications - Alexander Felix Kiefer
Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Campus E8.1, 66123, Saarbrücken, Germany
4 shared publications - Dong Yang
The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology
4 shared publications - Edward Kalkreuter
The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology
4 shared publications Song Meng
Department of Chemistry, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology, Jupiter, Florida 33458, United States
3 shared publications- Ajeeth Adhikari
The Herbert Wertheim UF Scripps Institute for Innovation & Technology
2 shared publications
Latest Publications
- 23 February 2026
- Published by Elsevier in Current Opinion in Chemical Biology
- Vol. 92, 102653
DVD-IgG1 antibody–drug conjugates: Expanding the landscape of targeted cancer therapy
- 23 February 2026
- Published by Elsevier in Current Opinion in Chemical Biology
- Vol. 92, 102653
DVD-IgG1 antibody–drug conjugates: Expanding the landscape of targeted cancer therapy
- 14 November 2025
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 147 (47) , 43424-43437
Chemical Tagging of N -Alkylamine-Containing Natural Products and Pharmaceuticals through C( sp 3 )–H Functionalization
The ability to introduce functional groups suitable for bioconjugation into natural products and pharmaceuticals in an efficient, chemo- and site-selective manner is critical for advancing drug discovery, biological chemistry, and targeted therapy. Late-stage C-H functionalization enables direct structural diversification of lead compounds, but broader application is constrained by the scarcity of catalysts that selectively activate relatively inert C-H bonds in polyfunctional drug compounds. Here, we report a photoinduced, flavin-catalyzed method that installs bioconjugation handles on a broad range of bioactive N-alkylamines. The transformation proceeds under mild, aerobic conditions with blue-light irradiation: flavin analogues mediate sequential α- and β-amino C-H bond scission to generate enamines, which undergo inverse electron-demand Diels-Alder reactions with tetrazine- or nitroalkene-based tagging agents. We assessed biological consequences by cytotoxicity and ligand-binding assays, revealing examples in which tagging either preserves or alters bioactivity. The method's versatility is demonstrated by the efficient synthesis of antibody-drug conjugates derived from the anticancer agent irinotecan.
- 14 November 2025
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 147 (47) , 43424-43437
Chemical Tagging of N -Alkylamine-Containing Natural Products and Pharmaceuticals through C( sp 3 )–H Functionalization
The ability to introduce functional groups suitable for bioconjugation into natural products and pharmaceuticals in an efficient, chemo- and site-selective manner is critical for advancing drug discovery, biological chemistry, and targeted therapy. Late-stage C-H functionalization enables direct structural diversification of lead compounds, but broader application is constrained by the scarcity of catalysts that selectively activate relatively inert C-H bonds in polyfunctional drug compounds. Here, we report a photoinduced, flavin-catalyzed method that installs bioconjugation handles on a broad range of bioactive N-alkylamines. The transformation proceeds under mild, aerobic conditions with blue-light irradiation: flavin analogues mediate sequential α- and β-amino C-H bond scission to generate enamines, which undergo inverse electron-demand Diels-Alder reactions with tetrazine- or nitroalkene-based tagging agents. We assessed biological consequences by cytotoxicity and ligand-binding assays, revealing examples in which tagging either preserves or alters bioactivity. The method's versatility is demonstrated by the efficient synthesis of antibody-drug conjugates derived from the anticancer agent irinotecan.
- 16 July 2025
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 64 (15) , 3418-3431
Coenzyme A Tethering Mediates Dehydratase Substrate Promiscuity and Reaction Specificity in Platensimycin, Platencin, and Platensilin Biosynthesis
Biosynthetic studies of the platensimycin (PTM), platencin (PTN), and platensilin (PTL) family of natural products have revealed numerous insights into the chemistry and enzymology of diterpenoid biosynthesis. A deeper understanding of the PTM biosynthetic machinery would advance fundamental knowledge in natural product biosynthesis and facilitate future efforts to exploit these compounds as potential leads for biomedical applications. Herein, we report the functional characterization of the ptmU1 gene that encodes the dehydratase responsible for the formation of the C6-C7 enone moiety in PTM, PTN, and PTL. In vitro experiments, enabled by the semisynthesis of designer substrates and mimics, reveal that PtmU1 is selective for multiple coenzyme A (CoA)-tethered substrates but specific only to the (7R)-hydroxyl group for dehydration. A combination of kinetics analyses, targeted mutagenesis, and in silico docking studies identifies an arginine-rich structural element of PtmU1 that acts as a dynamic CoA-binding anchor, revealing a unique strategy for CoA binding that presumably contributes to the substrate promiscuity and dehydration specificity of PtmU1. Finally, a bioinformatics investigation identifies PtmU1 homologues bearing this CoA-binding motif, suggesting that the observed biosynthetic chemistry might be broadly distributed. Taken together, these results shed new insights into PTM, PTN, and PTL biosynthesis and reveal a new perspective on the role of CoA in substrate binding and enzyme catalysis.
- 16 July 2025
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 64 (15) , 3418-3431
Coenzyme A Tethering Mediates Dehydratase Substrate Promiscuity and Reaction Specificity in Platensimycin, Platencin, and Platensilin Biosynthesis
Biosynthetic studies of the platensimycin (PTM), platencin (PTN), and platensilin (PTL) family of natural products have revealed numerous insights into the chemistry and enzymology of diterpenoid biosynthesis. A deeper understanding of the PTM biosynthetic machinery would advance fundamental knowledge in natural product biosynthesis and facilitate future efforts to exploit these compounds as potential leads for biomedical applications. Herein, we report the functional characterization of the ptmU1 gene that encodes the dehydratase responsible for the formation of the C6-C7 enone moiety in PTM, PTN, and PTL. In vitro experiments, enabled by the semisynthesis of designer substrates and mimics, reveal that PtmU1 is selective for multiple coenzyme A (CoA)-tethered substrates but specific only to the (7R)-hydroxyl group for dehydration. A combination of kinetics analyses, targeted mutagenesis, and in silico docking studies identifies an arginine-rich structural element of PtmU1 that acts as a dynamic CoA-binding anchor, revealing a unique strategy for CoA binding that presumably contributes to the substrate promiscuity and dehydration specificity of PtmU1. Finally, a bioinformatics investigation identifies PtmU1 homologues bearing this CoA-binding motif, suggesting that the observed biosynthetic chemistry might be broadly distributed. Taken together, these results shed new insights into PTM, PTN, and PTL biosynthesis and reveal a new perspective on the role of CoA in substrate binding and enzyme catalysis.
- Open Access
- 1 July 2025
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 5 (7) , 3171-3181
Second Generation Tiancimycin-Based Antibody–Drug Conjugates Enabled by Highly Efficient Semi-synthetic Approach Specifically Targeting B-Cell Malignancies
Antibody–drug conjugates (ADCs) are advanced cancer therapeutics that combine an antibody-based delivery system with a cytotoxic payload through chemical linkers. Anthraquinone-fused enediyne (AFE) natural products, such as tiancimycins (TNMs), are emerging payload candidates with exceptional potency and a validated DNA-damaging mechanism of action. In this study, we describe the translation of semisynthetically functionalized TNMs, incorporating various linker chemistries, into ADCs featuring dual variable domain monoclonal immunoglobulin G1 antibodies (DVD IgG1s). DVD IgG1s enable site-specific conjugation and modular antigen-targeting specificity. As a proof-of-principle, keto-TNM A-anti-CD79b DVD IgG1-based ADCs were constructed on the basis of the significance of CD79b as a clinical target, with only one FDA-approved ADC available. Inspired by the structure–activity relationship data, a chemical strategy to synthesize keto-TNM A was developed, which exhibited the highest potency among the TNMs we have examined to date. Keto-TNM A was elaborated to a panel of anti-CD79b DVD IgG1-based ADCs featuring varying linker chemistries. The optimized ADC exhibited potent and selective activity across multiple CD79b-expressing cell lines and, most significantly, patient-derived primary chronic lymphocytic leukemia cells. This study provides an efficient approach to access functionalized AFEs at scale and speed and exploit their utility as payloads for ADCs targeting CD79b and beyond as the next generation immunotherapies.
- 1 July 2025
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 5 (7) , 3171-3181
Open AccessSecond Generation Tiancimycin-Based Antibody–Drug Conjugates Enabled by Highly Efficient Semi-synthetic Approach Specifically Targeting B-Cell Malignancies
Antibody–drug conjugates (ADCs) are advanced cancer therapeutics that combine an antibody-based delivery system with a cytotoxic payload through chemical linkers. Anthraquinone-fused enediyne (AFE) natural products, such as tiancimycins (TNMs), are emerging payload candidates with exceptional potency and a validated DNA-damaging mechanism of action. In this study, we describe the translation of semisynthetically functionalized TNMs, incorporating various linker chemistries, into ADCs featuring dual variable domain monoclonal immunoglobulin G1 antibodies (DVD IgG1s). DVD IgG1s enable site-specific conjugation and modular antigen-targeting specificity. As a proof-of-principle, keto-TNM A-anti-CD79b DVD IgG1-based ADCs were constructed on the basis of the significance of CD79b as a clinical target, with only one FDA-approved ADC available. Inspired by the structure–activity relationship data, a chemical strategy to synthesize keto-TNM A was developed, which exhibited the highest potency among the TNMs we have examined to date. Keto-TNM A was elaborated to a panel of anti-CD79b DVD IgG1-based ADCs featuring varying linker chemistries. The optimized ADC exhibited potent and selective activity across multiple CD79b-expressing cell lines and, most significantly, patient-derived primary chronic lymphocytic leukemia cells. This study provides an efficient approach to access functionalized AFEs at scale and speed and exploit their utility as payloads for ADCs targeting CD79b and beyond as the next generation immunotherapies.
- 15 November 2024
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 146 (47) , 32605-32617
Structural Insights into the Mechanism of a Polyketide Synthase Thiocysteine Lyase Domain
Polyketide synthases (PKSs) are renowned for the structural diversity of the polyketide natural products they produce, but sulfur-containing functionalities are rarely installed by PKSs. We previously characterized thiocysteine lyase (SH) domains involved in the biosynthesis of the leinamycin (LNM) family of natural products, exemplified by LnmJ-SH and guangnanmycin (GnmT-SH). Here we report a detailed investigation into the PLP-dependent reaction catalyzed by the SH domains, guided by a 1.8 & Aring; resolution crystal structure of GnmT-SH. A series of elaborate substrate mimics were synthesized to answer specific questions garnered from the crystal structure and from the biosynthetic logic of the LNM family of natural products. Through a combination of bioinformatics, molecular modeling, in vitro assays, and mutagenesis, we have developed a detailed model of acyl carrier protein (ACP)-tethered substrate-SH, and interdomain interactions, that contribute to the observed substrate specificity. Comparison of the GnmT-SH structure with archetypical PLP-dependent enzyme structures revealed how Nature, via evolution, has modified a common protein structural motif to accommodate an ACP-tethered substrate, which is significantly larger than any of those previously characterized. Overall, this study demonstrates how PLP-dependent chemistry can be incorporated into the context of PKS assembly lines and sets the stage for engineering PKSs to produce sulfur-containing polyketides.
- 15 November 2024
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 146 (47) , 32605-32617
Structural Insights into the Mechanism of a Polyketide Synthase Thiocysteine Lyase Domain
Polyketide synthases (PKSs) are renowned for the structural diversity of the polyketide natural products they produce, but sulfur-containing functionalities are rarely installed by PKSs. We previously characterized thiocysteine lyase (SH) domains involved in the biosynthesis of the leinamycin (LNM) family of natural products, exemplified by LnmJ-SH and guangnanmycin (GnmT-SH). Here we report a detailed investigation into the PLP-dependent reaction catalyzed by the SH domains, guided by a 1.8 & Aring; resolution crystal structure of GnmT-SH. A series of elaborate substrate mimics were synthesized to answer specific questions garnered from the crystal structure and from the biosynthetic logic of the LNM family of natural products. Through a combination of bioinformatics, molecular modeling, in vitro assays, and mutagenesis, we have developed a detailed model of acyl carrier protein (ACP)-tethered substrate-SH, and interdomain interactions, that contribute to the observed substrate specificity. Comparison of the GnmT-SH structure with archetypical PLP-dependent enzyme structures revealed how Nature, via evolution, has modified a common protein structural motif to accommodate an ACP-tethered substrate, which is significantly larger than any of those previously characterized. Overall, this study demonstrates how PLP-dependent chemistry can be incorporated into the context of PKS assembly lines and sets the stage for engineering PKSs to produce sulfur-containing polyketides.
- 27 February 2024
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 87 (4) , 798-809
Biochemical and Structural Studies of the Carminomycin 4-O-Methyltransferase DnrK
Structural and functional studies of the carminomycin 4-O-methyltransferase DnrK are described, with an emphasis on interrogating the acceptor substrate scope of DnrK. Specifically, the evaluation of 100 structurally and functionally diverse natural products and natural product mimetics revealed an array of pharmacophores as productive DnrK substrates. Representative newly identified DnrK substrates from this study included anthracyclines, angucyclines, anthraquinone-fused enediynes, flavonoids, pyranonaphthoquinones, and polyketides. The ligand-bound structure of DnrK bound to a non-native fluorescent hydroxycoumarin acceptor, 4-methylumbelliferone, along with corresponding DnrK kinetic parameters for 4-methylumbelliferone and native acceptor carminomycin are also reported for the first time. The demonstrated unique permissivity of DnrK highlights the potential for DnrK as a new tool in future biocatalytic and/or strain engineering applications. In addition, the comparative bioactivity assessment (cancer cell line cytotoxicity, 4E-BP1 phosphorylation, and axolotl embryo tail regeneration) of a select set of DnrK substrates/products highlights the ability of anthracycline 4-O-methylation to dictate diverse functional outcomes.
- 27 February 2024
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 87 (4) , 798-809
Biochemical and Structural Studies of the Carminomycin 4-O-Methyltransferase DnrK
Structural and functional studies of the carminomycin 4-O-methyltransferase DnrK are described, with an emphasis on interrogating the acceptor substrate scope of DnrK. Specifically, the evaluation of 100 structurally and functionally diverse natural products and natural product mimetics revealed an array of pharmacophores as productive DnrK substrates. Representative newly identified DnrK substrates from this study included anthracyclines, angucyclines, anthraquinone-fused enediynes, flavonoids, pyranonaphthoquinones, and polyketides. The ligand-bound structure of DnrK bound to a non-native fluorescent hydroxycoumarin acceptor, 4-methylumbelliferone, along with corresponding DnrK kinetic parameters for 4-methylumbelliferone and native acceptor carminomycin are also reported for the first time. The demonstrated unique permissivity of DnrK highlights the potential for DnrK as a new tool in future biocatalytic and/or strain engineering applications. In addition, the comparative bioactivity assessment (cancer cell line cytotoxicity, 4E-BP1 phosphorylation, and axolotl embryo tail regeneration) of a select set of DnrK substrates/products highlights the ability of anthracycline 4-O-methylation to dictate diverse functional outcomes.
- 12 February 2024
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 63 (4) , 563-575
Discrete Acyltransferases and Thioesterases in Iso-Migrastatin and Lactimidomycin Biosynthesis
Iso-Migrastatin (iso-MGS) and lactimidomycin (LTM) are glutarimide-containing polyketide natural products (NPs) that are biosynthesized by homologous acyltransferase (AT)-less type I polyketide synthase (PKS) assembly lines. The biological activities of iso-MGS and LTM have inspired numerous efforts to generate analogues via genetic manipulation of their biosynthetic machinery in both native producers and model heterologous hosts. A detailed understanding of the MGS and LTM AT-less type I PKSs would serve to inspire future engineering efforts while advancing the fundamental knowledge of AT-less type I PKS enzymology. The mgs and ltm biosynthetic gene clusters (BGCs) encode for two discrete ATs of the architecture AT-enoylreductase (AT-ER) and AT-type II thioesterase (AT-TE). Herein, we report the functional characterization of the mgsB and ltmB and the mgsH and ltmH gene products, revealing that MgsB and LtmB function as type II thioesterases (TEs) and MgsH and LtmH are the dedicated trans-ATs for the MGS and LTM AT-less type I PKSs. In vivo and in vitro experiments demonstrated that MgsB was devoid of any AT activity, despite the presence of the conserved catalytic triad of canonical ATs. Cross-complementation experiments demonstrated that MgsH and LtmH are functionally interchangeable between the MGS and LTM AT-less type I PKSs. This work sets the stage for future mechanistic studies of AT-less type I PKSs and efforts to engineer the MGS and LTM AT-less type I PKS assembly lines for novel glutarimide-containing polyketides.
- 12 February 2024
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 63 (4) , 563-575
Discrete Acyltransferases and Thioesterases in Iso-Migrastatin and Lactimidomycin Biosynthesis
Iso-Migrastatin (iso-MGS) and lactimidomycin (LTM) are glutarimide-containing polyketide natural products (NPs) that are biosynthesized by homologous acyltransferase (AT)-less type I polyketide synthase (PKS) assembly lines. The biological activities of iso-MGS and LTM have inspired numerous efforts to generate analogues via genetic manipulation of their biosynthetic machinery in both native producers and model heterologous hosts. A detailed understanding of the MGS and LTM AT-less type I PKSs would serve to inspire future engineering efforts while advancing the fundamental knowledge of AT-less type I PKS enzymology. The mgs and ltm biosynthetic gene clusters (BGCs) encode for two discrete ATs of the architecture AT-enoylreductase (AT-ER) and AT-type II thioesterase (AT-TE). Herein, we report the functional characterization of the mgsB and ltmB and the mgsH and ltmH gene products, revealing that MgsB and LtmB function as type II thioesterases (TEs) and MgsH and LtmH are the dedicated trans-ATs for the MGS and LTM AT-less type I PKSs. In vivo and in vitro experiments demonstrated that MgsB was devoid of any AT activity, despite the presence of the conserved catalytic triad of canonical ATs. Cross-complementation experiments demonstrated that MgsH and LtmH are functionally interchangeable between the MGS and LTM AT-less type I PKSs. This work sets the stage for future mechanistic studies of AT-less type I PKSs and efforts to engineer the MGS and LTM AT-less type I PKS assembly lines for novel glutarimide-containing polyketides.
- Open Access
The Natural Products Discovery Center: Release of the First 8490 Sequenced Strains for Exploring Actinobacteria Biosynthetic Diversity
Actinobacteria, the bacterial phylum most renowned for natural product discovery, has been established as a valuable source for drug discovery and biotechnology but is underrepresented within accessible genome and strain collections. Herein, we introduce the Natural Products Discovery Center (NPDC), featuring 122,449 strains assembled over eight decades, the genomes of the first 8490 NPDC strains (7142 Actinobacteria), and the online NPDC Portal making both strains and genomes publicly available. A comparative survey of RefSeq and NPDC Actinobacteria highlights the taxonomic and biosynthetic diversity within the NPDC collection, including three new genera, hundreds of new species, and ∼7000 new gene cluster families. Selected examples demonstrate how the NPDC Portal’s strain metadata, genomes, and biosynthetic gene clusters can be leveraged using genome mining approaches. Our findings underscore the ongoing significance of Actinobacteria in natural product discovery, and the NPDC serves as an unparalleled resource for both Actinobacteria strains and genomes.
Open AccessThe Natural Products Discovery Center: Release of the First 8490 Sequenced Strains for Exploring Actinobacteria Biosynthetic Diversity
Actinobacteria, the bacterial phylum most renowned for natural product discovery, has been established as a valuable source for drug discovery and biotechnology but is underrepresented within accessible genome and strain collections. Herein, we introduce the Natural Products Discovery Center (NPDC), featuring 122,449 strains assembled over eight decades, the genomes of the first 8490 NPDC strains (7142 Actinobacteria), and the online NPDC Portal making both strains and genomes publicly available. A comparative survey of RefSeq and NPDC Actinobacteria highlights the taxonomic and biosynthetic diversity within the NPDC collection, including three new genera, hundreds of new species, and ∼7000 new gene cluster families. Selected examples demonstrate how the NPDC Portal’s strain metadata, genomes, and biosynthetic gene clusters can be leveraged using genome mining approaches. Our findings underscore the ongoing significance of Actinobacteria in natural product discovery, and the NPDC serves as an unparalleled resource for both Actinobacteria strains and genomes.
- 4 January 2023
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 66 (2) , 1562-1573
Application of a Biocatalytic Strategy for the Preparation of Tiancimycin-Based Antibody–Drug Conjugates Revealing Key Insights into Structure–Activity Relationships
Antibody-drug conjugates (ADCs) are cancer chemotherapeutics that utilize a monoclonal antibody (mAb)-based delivery system, a cytotoxic payload, and a chemical linker. ADC payloads must be strategically functionalized to allow linker attachment without perturbing the potency required for ADC efficacy. We previously developed a biocatalytic system for the precise functionalization of tiancimycin (TNM)-based payloads. The TNMs are anthraquinone-fused enediynes (AFEs) and have yet to be translated into the clinic. Herein, we report the translation of biocatalytically functionalized TNMs into ADCs in combination with the dual-variable domain (DVD)-mAb platform. The DVD enables both site-specific conjugation and a plug-and-play modularity for antigen-targeting specificity. We evaluated three linker chemistries in terms of TNM-based ADC potency and antigen selectivity, demonstrating a trade-off between potency and selectivity. This represents the first application of AFE-based payloads to DVDs for ADC development, a workflow that is generalizable to further advance AFE-based ADCs for multiple cancer types.
- 4 January 2023
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 66 (2) , 1562-1573
Application of a Biocatalytic Strategy for the Preparation of Tiancimycin-Based Antibody–Drug Conjugates Revealing Key Insights into Structure–Activity Relationships
Antibody-drug conjugates (ADCs) are cancer chemotherapeutics that utilize a monoclonal antibody (mAb)-based delivery system, a cytotoxic payload, and a chemical linker. ADC payloads must be strategically functionalized to allow linker attachment without perturbing the potency required for ADC efficacy. We previously developed a biocatalytic system for the precise functionalization of tiancimycin (TNM)-based payloads. The TNMs are anthraquinone-fused enediynes (AFEs) and have yet to be translated into the clinic. Herein, we report the translation of biocatalytically functionalized TNMs into ADCs in combination with the dual-variable domain (DVD)-mAb platform. The DVD enables both site-specific conjugation and a plug-and-play modularity for antigen-targeting specificity. We evaluated three linker chemistries in terms of TNM-based ADC potency and antigen selectivity, demonstrating a trade-off between potency and selectivity. This represents the first application of AFE-based payloads to DVDs for ADC development, a workflow that is generalizable to further advance AFE-based ADCs for multiple cancer types.